Calendar

Sep
7
Tue
How Can You Use Targeted Therapies to Improve Clinical Decision-Making and Health Outcomes for Veterans with Acute Myeloid Leukemia?
Sep 7 2021 @ 12:00 am – Sep 7 2022 @ 3:20 am

How Can You Use Targeted Therapies to Improve Clinical Decision-Making and Health Outcomes for Veterans with Acute Myeloid Leukemia?

View Activity

PROGRAM CHAIR & FACULTY PRESENTER

Michael R. Grunwald, MD
Chief, Leukemia Division
Levine Cancer Institute, Atrium Health
Charlotte, NC

PROGRAM OVERVIEW

This activity will explore the management of patients with newly diagnosed, relapsed/refractory, and secondary acute myeloid leukemia (AML).

EDUCATIONAL AUDIENCE

This educational activity is intended for hematologists, community oncologists and clinicians involved in the assessment, monitoring, and treatment of AML in the Department of Veterans Affairs.

LEARNING OBJECTIVES

Upon completion of the program, attendees should be able to:

  • Evaluate how genetic and molecular markers aid in determining treatment strategies for patients with AML
  • Personalize therapy for the treatment of newly diagnosed, relapsed/refractory (R/R), and secondary AML based on disease‐ and patient‐specific factors and communicate these treatment plans using shared decision-making strategies in the inpatient and outpatient settings
  • Identify adverse events associated with AML treatment to appropriately prevent and/or manage these potential effects

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care and treatment of patients with AML.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Michael R. Grunwald, MD, reports the following disclosures:

  • Consulting: AbbVie, Agios, Amgen, Astellas, Blueprint Medicines, Bristol Myers Squibb, Cardinal Health, Daiichi Sankyo, Gamida Cell, Gilead, Incyte, Invitae, Karius, Ono Pharmaceutical, Pfizer, Premier, Sierra Oncology, Stemline
  • Research funding (institution): Incyte, Janssen
  • Stock ownership: Medtronic

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP Educational Development for Med Learning Group has nothing to disclose.
Jessica McMullen, MPH, Program Manager for Med Learning Group has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete the online evaluation form.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

RELEASE DATE: September 7, 2021

EXPIRATION DATE: September 7, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

View Activity

 

Sep
29
Wed
How Can You Improve Your Approaches to Care for Veterans with Chronic Lymphocytic Leukemia? Insights from the Experts
Sep 29 2021 @ 8:00 am – Sep 29 2022 @ 9:00 am

How Can You Use Targeted Therapies to Improve Clinical Decision-Making and Health Outcomes for Veterans with Acute Myeloid Leukemia?

View Activity

 

PROGRAM CHAIR AND SPEAKING FACULTY
Ryan Jacobs, MD
Principal Investigator of CLL Clinical Trials
Department of Hematology, Lymphoma Division
Levine Cancer Institute/Atrium Health
Charlotte, NC

PROGRAM OVERVIEW
This activity will cover the assessment, monitoring, and treatment of chronic lymphocytic leukemia (CLL) in the Department of Veterans Affairs.

TARGET AUDIENCE
This educational activity is intended for community oncologists, hematologists, and clinicians involved in the assessment, monitoring, and treatment of CLL in the Department of Veterans Affairs.

LEARNING OBJECTIVES
On completing the program, attendees should be able to:
• Assess how genetic and molecular markers aid in determining treatment strategies for patients with CLL
• Evaluate the role of minimal residual disease (MRD) in monitoring the effectiveness of treatment approaches for CLL and its clinical implications
• Individualize selection of therapies for the treatment of treatment-naïve and relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate these treatment plans using shared decision-making strategies
• Recognize adverse events associated with CLL treatment to appropriately prevent and/or manage these potential effects

ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with CLL.
CNE Credits: 1.0 ANCC Contact Hour

CNE Accreditation Statement:
Ultimate Medical Academy/ Complete Conference Management (CCM) is accredited as a provider of continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Faculty Member Disclosure
Ryan Jacobs, MD Dr. Jacobs reports that he serves as a consultant for AstraZeneca, Secura Bio, Genentech, Adaptive, and TG Therapeutics. He also serves on speakers bureaus for Pharmacyclics, Janssen, AbbVie, TG Therapeutics, Secura Bio and AstraZeneca. Dr. Jacobs has also completed contracted research for Pharmacyclics, Teneobio, MEI Pharma, and TG Therapeutics.

 

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer:
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
• Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
• Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
• Marcello Morgan, MD, MPH, Medical and Scientific Services for Med Learning Group has nothing to disclose.
• Lauren Bartunek, Program Manager for Med Learning Group, has nothing to disclose.
• Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
• Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
• Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.

DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures
2. Participate in the enduring activity
3. Complete posttest and evaluation form online.
You will receive your certificate as a downloadable file.

DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

RELEASE DATE: September 29, 2021

EXPIRATION DATE: September 29, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

View Activity

Nov
5
Fri
CATALYST: Insights from the Experts to Navigate a Complex and Evolving Landscape in CLL and AML Management
Nov 5 2021 @ 1:55 am – Nov 5 2022 @ 2:55 am

CATALYST: Insights from the Experts to Navigate a Complex and Evolving Landscape in CLL and AML Management

View Activity

FACULTY

Michael R. Grunwald, MD
Chief, Leukemia Division
Associate Professor, Atrium Health
Department of Hematologic Oncology and Blood Disorders
Levine Cancer Institute
Charlotte, NC

Ryan Jacobs, MD
Department of Hematology, Lymphoma Division
Assistant Professor of Medicine
Levine Cancer Institute/Atrium Health
Charlotte, NC

PROGRAM OVERVIEW

This enduring activity will cover the treatment and management of patients with AML and CLL.

TARGET AUDIENCE

This activity is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with CLL and/or AML.

LEARNING OBJECTIVES

Upon completion of the program, attendees should be able to:

  • Determine how genetic and molecular markers aid in determining treatment strategies for patients with either CLL or AML
  • Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL or AML based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
  • Distinguish adverse events associated with either CLL or AML treatment to appropriately prevent and/or manage potential effects

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 2.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with AML and CLL.

Credits: 2.0 ANCC Contact Hours.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 2.0 contact hours of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Michael R. Grunwald, MD receives consulting fees from AbbVie, Agios, Amgen, Astellas, Blueprint Medicines, Bristol Myers Squibb, Cardinal Health, Daiichi Sankyo, Gilead, Incyte, Karius, Pfizer, Premier, Sierra Oncology, and Stemline Therapeutics; receives research funding (institution) from Incyte and Janssen; and has stock ownership in Medtronic.

Ryan Jacobs, MD serves on a speaker bureau for AbbVie, AstraZeneca, Janssen, Pharmacyclics, Secura Bio and TG Therapeutics; serves as consultant for Adaptive, AstraZeneca, Genentech, Secura Bio, and TG Therapeutics; and receives research funding from MEI Pharma Pharmacyclics, Teneobio and TG Therapeutics.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose

Staff, Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP Educational Development for Med Learning Group has nothing to disclose.
Felecia Beachum, Program Manager for Med Learning Group has nothing to disclose.
Deb Gordon, Medical Director for Med Learning Group, owns stock in AbbVie and Merck.
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.  During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making skills before applying any information, whether provided here or by others, for any professional use.

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

RELEASE DATE: November 05, 2021

EXPIRATION DATE: November 05, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

View Activity

 

Nov
12
Fri
How Can You Use Newer Therapies to Improve Clinical Decision-Making and Long-term Health Outcomes for Patients with Acute Myeloid Leukemia?
Nov 12 2021 @ 5:27 pm – Nov 12 2022 @ 6:27 pm

How Can You Use Newer Therapies to Improve Clinical Decision-Making and Long-term Health Outcomes for Patients with Acute Myeloid Leukemia?

View Activity

PROGRAM CHAIR

David Rizzieri, MD
Senior Vice President and Director
Novant Health Cancer Institute
Charlotte, NC

SPEAKER FACULTY

Alice S. Mims, MD, MSCR
Acute Leukemia Clinical Research Director
Associate Professor of Internal Medicine
The James Comprehensive Cancer Center
The Ohio State University
Columbus, OH

PROGRAM OVERVIEW

This activity will cover the assessment, monitoring, and treatment of Acute Myeloid Leukemia (AML).

TARGET AUDIENCE

This educational activity is intended for community oncologists and advanced practice oncology clinicians involved in the assessment, monitoring, and treatment of AML.

LEARNING OBJECTIVES

On completing the program, attendees should be able to:

  • Evaluate how genetic and molecular markers aid in determining treatment strategies for patients with AML
  • Assess clinical efficacy and safety data for newer formulations and novel targeted therapies used to manage patients with AML
  • Personalize therapy for the treatment of newly diagnosed, relapsed/refractory (R/R), and secondary AML based on disease‐ and patient‐specific factors to communicate these treatment plans using shared decision-making strategies in the inpatient and outpatient settings
  • Identify adverse events associated with AML treatment to appropriately prevent and/or manage these potential effects

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved and/or interested in the assessment, monitoring, and treatment of AML.

CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Faculty Member Disclosures
David Rizzieri, MD Dr. Rizzieri reports that he serves on the speakers bureaus for Celgene, Gilead, Seattle Genetics and Stemline, Novartis, Pfizer, Sanofi, Incyte, Morphosys, BMS, Jazz, Astellas. He is also on the advisory board for AbbVie, Agios, AROG, Bayer, Celgene, Gilead, Jazz, Novartis, Pfizer, Sanofi, Seattle Genetics, Stemline, Teva, Kite, Incyte, Amgen, Acrobiotech, Cellectis, and Chimerix, Inc. Dr. Rizzieri is a consultant for AbbVie, Agios, AROG, Bayer, Celgene, Celltrion, Mustang, Pfizer, Seattle Genetics, Stemline, Kite, Incyte, Amgen, Acrobiotech, Cellectis, and Chimerix, Inc and Gilead. He has also done Data Safety Monitoring for Chimerix, Inc. and Cellectis, in addition to the UCARRT Study.
Alice S. Mims, MD, MSCR Dr. Mims reports that she serves as a consultant for AbbVie, Genentech, Jazz Pharmaceuticals, Daiichi Saynko, BMS, and Syndax Pharmaceuticals.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer:

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Debra Gordon, MS, Medical Director for Med Learning Group has nothing to disclose.
Lauren Bartunek, Program Manager for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CNE credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures
  2. Participate in the enduring activity
  3. Complete posttest and evaluation form online.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based.

This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

RELEASE DATE: November 12, 2021

EXPIRATION DATE: November 12, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy‐policy/

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

View Activity

 

Mar
2
Wed
Assessing the Growing Evidence in Alopecia Areata: The Role of JAK Inhibitors
Mar 2 2022 @ 7:56 pm – Mar 2 2023 @ 8:56 pm

Assessing the Growing Evidence in Alopecia Areata: The Role of JAK Inhibitors

View Activity

FACULTY

Bianca Maria Piraccini, MD (Program Chair)
Professor
Head of Division of Dermatology
Department of Experimental, Diagnostic and Specialty Medicine – DIMES
University of Bologna
Bologna, Italy

SPEAKER FACULTY

Justin M Ko, MD, MBA
Clinical Professor, Dermatology
Stanford Hospital and Clinics Lucile Packard Children’s Hospital
Stanford, California

PROGRAM OVERVIEW

This enduring activity will discuss the causes of alopecia areata and how to best manage this disease. Expert faculty will highlight the burden of alopecia areata and will offer participants strategies for implementing treatment plans that will not only address the disease itself, but also the overall health challenges for this patient population.

TARGET AUDIENCE

This educational enduring activity is intended for dermatology professionals who care for patients with alopecia areata.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Explain the autoimmune mechanisms of current and emerging treatments for AA
  • Determine which patients with AA are and are not candidates for JAK inhibitors
  • Create treatment plans for patients with AA that address the comorbidities and psychosocial impacts of the disease

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: Education for managing alopecia areata, including current and new treatments, leads to safe practice, quality care, and continuous professional and personal development for nurses.

CNE Credits: 1.0 ANCC Contact Hour

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Faculty Relationship Manufacturer
Bianca Maria Piraccini, MD Nothing to disclose
Justin M Ko, MD, MBA Consultant Eli Lilly & Pfizer

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
  • Angela L. Davis, PhD, Director of Medical and Scientific Services for Med Learning Group, has nothing to disclose.
  • Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
  • Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this live virtual activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures
  2. Participate in the live virtual activity
  3. Submit the pre- and post-test and evaluation form to Med Learning Group

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

RELEASE DATE: March 02, 2022

EXPIRATION DATE: March 02, 2023

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

View Activity

 

Mar
4
Fri
The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL
Mar 4 2022 @ 9:27 pm – Mar 4 2023 @ 10:27 pm

The CATALYST Initiative: Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies: A Focus on CLL

View Activity

FACULTY

Ryan Jacobs, MD (PROGRAM CHAIR)
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC

PROGRAM OVERVIEW

This case-based enduring activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.

TARGET AUDIENCE

This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
  • Differentiate therapy for the treatment of newly diagnosed or relapsed/ refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
  • Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with chronic lymphocytic leukemia.

CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST
Ryan Jacobs, MD reports that he serves as a consultant for AstraZeneca, Secura Bio, Genentech, Adaptive, and TG Therapeutics. He also serves on speakers’ bureaus for Pharmacyclics, Janssen, AbbVie, TG Therapeutics, Secura Bio and AstraZeneca. Dr. Jacobs has also completed contracted research for Pharmacyclics, Teneobio, MEI Pharma, and TG Therapeutics.

CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.

Teresa L. Keating, MSN, RN, WHNP
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose
Staff Planners and Managers
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Teresa L. Keating, MSN, RN, WHNP, UMA/CMM – LNP, has nothing to disclose.
Debra Gordon, Medical Director of Med Learning Group, has nothing to disclose.
Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
Jessica Feygin, Program Coordinator of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Daniel Dasilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME/CE credit for this enduring activity. To receive CME/CE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

RELEASE DATE: March 04, 2022

EXPIRATION DATE: March 04, 2023

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

View Activity

 

May
26
Thu
Insights in Acute Myeloid Leukemia: Optimizing System Level Quality for Our Veterans
May 26 2022 @ 7:17 pm – May 26 2023 @ 8:17 pm

Insights in Acute Myeloid Leukemia: Optimizing System Level Quality for Our Veterans

View Activity

PROGRAM CHAIR & FACULTY PRESENTER

Michael R. Grunwald, MD
Chief, Leukemia Division
Director, Transplantation and Cellular Therapy Program
Associate Professor
Levine Cancer Institute, Atrium Health
Charlotte, NC

PROGRAM OVERVIEW

This activity will explore the management of patients with of newly diagnosed and relapsed/refractory acute myeloid leukemia (AML). This program will address the role of genetic and molecular markers in treatment selection as well as best practices for treatment of newly diagnosed, and relapsed/refractory, and secondary AML. A summary of approaches to TRAE recognition and mitigation will also be discussed.

TARGET AUDIENCE

This educational activity is intended for hematologists, community oncologists and clinicians involved in the assessment, monitoring, and treatment of AML in the Department of Veterans Affairs.

LEARNING OBJECTIVES

Upon completion of the program, attendees should be able to:

  • Evaluate the role of genetic and molecular markers in treatment options for patients with AML
  • Assess best practices for clinical management of newly diagnosed, and relapsed/refractory AML, as well as secondary AML, and implement shared decision-making across treatment plans
  • Summarize possible adverse events associated with AML treatment and understand best practices for identification and management of potential adverse events

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with acute myeloid leukemia.

CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Grunwald has received consulting fees from AbbVie, Agios/Servier, Amgen, Astellas Pharma, Blueprint Medicines, Bristol Myers Squibb, Cardinal Health, CTI Biopharma, Daiichi Sankyo, Gamida Cell, Gilead Sciences, Incyte Corporation, Invitae, Novartis, Ono Pharmaceutical, Pfizer, Premier, Sierra Oncology, and Stemline; he has also been contracted for research with Janssen, and holds stock in Medtronic.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
James Seternus, DO, Medical & Scientific Services for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Jessica McMullen, MPH, Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the online post-test and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

RELEASE DATE: May 26, 2022

EXPIRATION DATE: May 26, 2023

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

View Activity